Oncology

Back to articles

Newer Agents Effective for Chronic Myeloid Leukemia, Solid Tumors

KEY POINT

Results of recently published studies contribute to an increased value and utility of tyrosine kinase inhibitors and aromatase inhibitors for treatment of a variety of cancers, including chronic myeloid leukemia (CML), nonsmall cell lung cancer (NSCLC), and breast cancer.

SOURCES

Hughes TP et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–32. 

Kris MG et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–58.

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349;1793–802. 

Bryant J, Wolmark N. Letrozole after tamoxifen for breast cancer—what is the price of success [editorial]? N Engl J Med. 2003;349:1855–7. 

Burstein HJ. Beyond tamoxifen—extending endocrine treatment for early-stage breast cancer [editorial]. N Engl J Med. 2003;349:1857–9.